With the funding of $10.3 mn led by Spero ventures, Oova meets evolving needs of women’s fertility and looks to expand to more areas of women’s health.
Our Bureau
New York, NY
Oova announced its Series A raise of $10.3 mn, and introduced the new Oova Membership model, designed to provide unparalleled support and empowerment to women as they navigate fertility while trying to conceive. Unlike traditional one-time purchases or subscription-to-refill kits, the Oova Membership offers a comprehensive, ongoing solution for women’s reproductive health.
Amy Divaraniya, Oova founder and CEO, is a Ph.D. and an expert in biomedical sciences with a focus on genetics. It was her personal struggle to conceive due to an irregular menstrual cycle and realizing the lack of resources women have to access instrumental information about their own bodies, drove Divaraniya to develop Oova’s revolutionary technology emphasized, leading Divaraniya to the development of Oova’s revolutionary technology.
Oova is the only test in the market that quantitatively measures luteinizing hormone (LH) and progesterone (PdG) in real-time, providing women with daily insights and actionable advice to optimize their chances of conception. FDA-registered, Oova is the only product that allows its users to sync and share results with their doctor in real-time. This innovative approach sets Oova apart, empowering women and their doctors with the knowledge they need to make informed decisions about their reproductive health. Launched in 2021, Oova Kit has already trained its model on over 10,000 cycles monitored through the platform.
Led by Spero Ventures, a firm committed to companies with a positive mission, who are creating new markets and solutions for their customers and joined by other strategic firms including US Fertility, Virgin Group, Jefferson Health, Connecticut Innovations, Special Situations Life Sciences Fund, Samsung Next, Hannah Bronfman, and Sara Blakely, the acclaimed businesswoman and founder of Spanx – this round of funding brought renowned investors across various industries and executive level expertise.
“Oova has revolutionized the way we understand our hormonal health,” said Sara Eshelman, partner at Spero Ventures. “By making clinical-grade hormone monitoring convenient and cost-effective for daily use, Oova is empowering its users to understand their cycles, improve fertility outcomes, and manage their symptoms. Simultaneously, Oova offers intricate datasets that provide patients and clinicians an unprecedented objective understanding of how hormones affect our health and well-being. We re honored to be part of the team’s mission to bring these capabilities to women, and to clinical care as a whole,” she added.
“The US Fertility Innovation Fund is proud to partner with and invest in companies with the potential to transform the reproductive space. Oova is poised to do so by providing a more convenient and cost-effective way to measure reproductive hormones at home,” stated Dr Eduardo Hariton, Managing Director of US Fertility Innovation Fund. “Their essays have been rigorously validated and provide accurate results in minutes, allowing them to meet the unique needs of both patients and providers without some of the hurdles of venipuncture.” he continued.
Understanding the evolving needs of women on their fertility journeys, Oova launched the Oova membership to address these needs holistically. Priced at $99 per month, the membership includes The Oova Kit ($159 value) and offers an array of features for women at every step of their fertility journey, including personalized support from Oova’s network of professionals.
The membership includes comprehensive support, personalized guidance and Community Connection. By engaging with this community of like-minded women who are on their journeys to parenthood, members can share their experiences, seek support, and forge valuable connections, creating a sense of camaraderie throughout their fertility journeys.
“We recognize that women seeking to start or expand their families desire more than just a test or a tool—they want a comprehensive solution,” said Divaraniya. “With the introduction of the Oova Membership, we are excited to provide women with a plan for the next steps in their journey to parenthood. By combining expert guidance, personalized recommendations, and a supportive community, we aim to empower women and ensure they have the tools they need to make informed decisions about their reproductive health.”
